Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 22, 2026, 10:09 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 3,858 matching trials from the live ClinicalTrials.gov search.
Completed No phase listed Observational Accepts healthy volunteers

MRI Markers of Outcome After Severe Pediatric TBI

NCT02688660
Conditions
Brain Injuries
Interventions
MRI Scans
Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
0 Years to 18 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
18
States / cities
Phoenix, Arizona • San Diego, California • Washington D.C., District of Columbia + 15 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women

NCT01977625
Conditions
Menopause, Brain Activity, Cognition
Interventions
Lisdexamfetamine, Placebo
Drug · Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Fallopian Tube High Grade Serous Adenocarcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian High Grade Serous Adenocarcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma
Interventions
Computed Tomography, Copanlisib Hydrochloride, Magnetic Resonance Imaging, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
Aurora, Colorado • Iowa City, Iowa • Cleveland, Ohio + 2 more
Conditions
Covid19, Coma, Consciousness Disorder
Interventions
Functional MRI
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
12 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Prostate Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Gallium Ga 68-labeled PSMA-11, Monosodium Glutamate, Positron Emission Tomography
Procedure · Drug · Dietary Supplement
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Los Angeles, California
Terminated No phase listed Observational Accepts healthy volunteers

MRS and Medication Response: A Pilot Study

NCT03254342
Conditions
Major Depressive Disorder, Major Depressive Episode, Major Depressive Disorder, Recurrent, Major Depression Mild, Major Depression Moderate, Major Depression Severe
Interventions
Not listed
Lead sponsor
Stanford University
Other
Eligibility
21 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2020
U.S. locations
1
States / cities
Stanford, California
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Male Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
Fluorothymidine F-18, Positron Emission Tomography, Laboratory Biomarker Analysis, Run-in (short pre-surgery course) of endocrine-targeted therapy
Drug · Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Pediatric Radio Frequency Coils Generic

NCT01633866
Conditions
Duchenne Muscular Dystrophy, Musculoskeletal Abnormalities
Interventions
Not listed
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
Not listed
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Terminated Not applicable Interventional Accepts healthy volunteers

DCE MRI in Patients With Pancreatic Cancer

NCT02070705
Conditions
Familial Pancreatic Cancer, Pancreatic Adenocarcinoma, Pancreatic Intraductal Papillary-Mucinous Neoplasm
Interventions
Dynamic Contrast-Enhanced Magnetic Resonance Imaging, Ferumoxytol
Procedure · Drug
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 85 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Completed Phase 2 Interventional Results available

A Pilot Study of KPL-914 in Recurrent Pericarditis

NCT03980522
Conditions
Recurrent Pericarditis
Interventions
KPL-914
Drug
Lead sponsor
Kiniksa Pharmaceuticals (UK), Ltd.
Industry
Eligibility
6 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
14
States / cities
Washington D.C., District of Columbia • DeLand, Florida • Jacksonville, Florida + 11 more
Not listed Not applicable Interventional Accepts healthy volunteers

Can Therapy Alter CNS Processing of Chronic Pain: A Longitudinal Study

NCT01794988
Conditions
Chronic Pain
Interventions
Group Cognitive Behavioral Therapy, Pain Education, Therapeutic Interactive Voice Response, NO TIVR
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Burlington, Vermont
Conditions
Inflammatory Bowel Disease, Crohn Disease
Interventions
Coronal T1 weighted spin echo images, Spin-lattice relaxation (T1), Magnetic resonance spectroscopy, Blood Draw
Diagnostic Test
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
13 Years to 20 Years
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Glioblastoma
Interventions
Radiologic exams
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Boston, Massachusetts
Recruiting Phase 4 Interventional

The Role of mGluR5 in CBT-I

NCT07076342
Conditions
Major Depressive Disorder (MDD)
Interventions
Cognitive Behavioral Therapy for Insomnia, PET Scan with [11C]ABP688
Behavioral · Drug
Lead sponsor
Stony Brook University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Stony Brook, New York
Conditions
Non-small Cell Lung Cancer, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Ductal Adenocarcinoma of the Pancreas
Interventions
AGuIX, Radiotherapy
Drug · Radiation
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Disseminated Neuroblastoma, Recurrent Neuroblastoma
Interventions
ABT-751, quality-of-life assessment
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
11
States / cities
Birmingham, Alabama • Chicago, Illinois • Boston, Massachusetts + 8 more
Completed No phase listed Observational Accepts healthy volunteers

Neuroimaging of Dystonia

NCT02046447
Conditions
Primary Cervical Dystonia, DYT 1 Dystonia
Interventions
Primary Cervical Dystonia (Trihexyphenidyl), Controls Primary Cervical Dystonia (Trihexyphenidyl), DYT 1 Dystonia (Healthy Control), DYT 1 Dystonia
Drug · Other
Lead sponsor
University of Florida
Other
Eligibility
7 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Gainesville, Florida
Suspended Not applicable Interventional Accepts healthy volunteers

Evaluation of Muscle Oxygen With MRI

NCT07638384
Conditions
Muscle Oxygenation
Interventions
Compression and Contraction
Procedure
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
20 Years to 64 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
New York, New York
Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
Interventions
Atezolizumab, Biopsy, Biospecimen Collection, Computed Tomography, Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography and Computed Tomography Scan
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
9
States / cities
Riverside, California • Tampa, Florida • Honolulu, Hawaii + 5 more
Conditions
Advanced Fallopian Tube Carcinoma, Advanced Fallopian Tube High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian High Grade Serous Adenocarcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Primary Peritoneal High Grade Serous Adenocarcinoma, Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IV Ovarian Cancer 2014, Ovarian Mixed Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma
Interventions
Biopsy, Biospecimen Collection, Computed Tomography, Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed, Leukapheresis, Magnetic Resonance Imaging, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine, Placebo Administration, Tetanus and Diphtheria Toxoids Adsorbed
Procedure · Biological · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
3
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota
Completed Not applicable Interventional Results available

Advisa MRI Clinical Study

NCT01110915
Conditions
Magnetic Resonance Imaging, Cardiac Pacemaker, Artificial
Interventions
Medtronic Advisa MRI Implantable Pulse Generator (IPG), Medtronic CapSureFix MRI™ active fixation MRI lead
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
Not listed
Enrollment
269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
Salinas, California • Orlando, Florida • West Des Moines, Iowa + 8 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer

NCT03400215
Conditions
Breast Cancer
Interventions
Diagnostic Breast Cancer Scan, Research Scan for Gradient-echo Spectroscopic Imaging (GSI)
Diagnostic Test
Lead sponsor
NYU Langone Health
Other
Eligibility
25 Years to 99 Years · Female only
Enrollment
190 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
New York, New York
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

An Imaging-based Quantitative Biomarker Assay for NAFLD in Children

NCT06354491
Conditions
NAFLD, NASH
Interventions
Magnetic Resonance Imaging (MRI), Ultrasound (US)
Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
10 Years to 14 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Locally Advanced Unresectable Uveal Melanoma
Interventions
Tebentafusp-Tebn
Drug
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
2
States / cities
Philadelphia, Pennsylvania